Alumis, Inc. | MedPath

Robust Pipeline of 80+ Therapies Advancing in Psoriasis Treatment Landscape

a month ago

• DelveInsight's 2025 Psoriasis Pipeline Report reveals over 80 companies developing 80+ pipeline therapies, highlighting significant R&D investment in this therapeutic area. • Promising treatments in development include topical roflumilast (Arcutis Biotherapeutics) in Phase III trials and GSK2982772 (GlaxoSmithKline), a novel RIPK1 inhibitor in Phase I development. • Alumis Inc. has initiated a long-term extension study for ESK-001 in moderate to severe plaque psoriasis patients, evaluating safety, efficacy, and durability of response over 24 weeks.

Alumis to Present 52-Week Phase 2 Data for Novel TYK2 Inhibitor in Psoriasis at AAD 2025

3 months ago

• Alumis will showcase long-term safety and efficacy data for ESK-001, their oral TYK2 inhibitor, in moderate-to-severe plaque psoriasis through multiple presentations at the 2025 AAD annual meeting. • The company has accelerated the timeline for their Phase 3 ONWARD program, with topline data now expected in Q1 2026, reflecting strong patient enrollment and investigator interest. • ESK-001 demonstrated sustained PASI score improvements and favorable safety profile in interim 28-week open-label extension data, with most patients achieving PASI 75 at the 40mg twice-daily dose.

Alumis and Acelyrin Announce Merger to Create $737M Clinical-Stage Biopharma Company

4 months ago

• Alumis and Acelyrin have agreed to merge in an all-stock transaction, creating a combined entity with $737 million in cash runway extending into 2027. • The merged company will retain the Alumis name and prioritize development of two TYK2 inhibitors targeting conditions including psoriasis, lupus, and multiple sclerosis. • Acelyrin's thyroid eye disease drug lonigutamab is included in the deal but will undergo strategic review to assess its market differentiation potential.

Multiple Sclerosis Pipeline Shows Promise with Novel Therapies in Development

6 months ago

• The multiple sclerosis (MS) therapeutic landscape is expanding, with over 80 active pipeline therapies currently in development by more than 75 companies. • Recent clinical trials have yielded mixed results, with some therapies showing promise in specific MS subtypes, such as non-relapsing secondary progressive MS (nrSPMS). • Regulatory milestones have been achieved, including FDA approval for new formulations and fast-track designations for therapies targeting progressive MS. • Emerging therapies in the MS pipeline include monoclonal antibodies, oral treatments, and CAR-T cell therapies, offering diverse mechanisms of action and routes of administration.

Alumis' Oral TYK2 Inhibitor ESK-001 Shows Sustained Efficacy in Psoriasis Phase 2 Extension

8 months ago

• Alumis Inc. announced positive 28-week data from the open-label extension of its Phase 2 STRIDE trial of ESK-001 for moderate-to-severe plaque psoriasis. • The data showed that 93% of patients on the 40 mg twice-daily dose achieved PASI 75, demonstrating sustained efficacy over time. • ESK-001 continued to exhibit a favorable safety profile, with most treatment-emergent adverse events being mild to moderate. • Alumis expects to report full 52-week OLE data in the first half of 2025 and is advancing ESK-001 in the Phase 3 ONWARD clinical program.